KA
GBT

Kerrisdale Advisers’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Kerrisdale Advisers’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-84,132
Closed -$2.95M – 66
2021
Q2 		$2.95M Hold
84,132
– – 0.26% 43
2021
Q1 		$3.43M Buy
84,132
+25,000
+42% +$1.15M 0.26% 43
2020
Q4 		$2.56M Buy
+59,132
New +$2.92M 0.2% 54

Other funds holding GBT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Kerrisdale Advisers's GBT Position: Q3 2021 in Review

Kerrisdale Advisers sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2021, closing a stake of 84,132 shares — an estimated $2.95M sold.

Kerrisdale Advisers first reported a position in GBT in Q4 2020 and held it in 3 quarters. The position peaked at $3.43M in Q1 2021. 187 funds tracked by Wall St. Rank hold GBT as of Q3 2021.

  • Kerrisdale Advisers reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Kerrisdale Advisers sold 84,132 Global Blood Therapeutics, Inc. shares in Q3 2021, an estimated $2.95M.
  • Kerrisdale Advisers first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 3 quarters.
  • Kerrisdale Advisers's Global Blood Therapeutics, Inc. position peaked at $3.43M in Q1 2021.
  • 187 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2021.

Based on Kerrisdale Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.